サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：尿素サイクル異常症治療市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年
市場調査レポート
商品コード
1321050

尿素サイクル異常症治療市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年

Urea Cycle Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Enzyme Deficiency Type, By Treatment Type, By Route of Administration, By Distribution Channel, By Company, and By Region

出版日
ページ情報
英文 111 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

尿素サイクル異常症治療市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年
出版日: 2023年08月01日
発行: TechSci Research
ページ情報: 英文 111 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の尿素サイクル異常症治療市場は、予測期間2023～2027年に目覚ましい成長を遂げると予測されています。

主な要因としては、尿素サイクル異常症の有病率の増加、広範な研究開発が世界の市場の成長を牽引しています。尿素サイクル異常症（UCD）は、肝周囲細胞で尿素サイクルを構成する遺伝子異常のグループです。市場の成長を支えるその他の要因としては、政府による研究開発活動への投資の増加、主要企業によるイニシアティブの強化、大衆の意識の高まり、より良いヘルスケアサービスの存在、革新的な診断アプローチの増加などが挙げられます。

人口における尿素サイクル異常症の有病率の上昇

尿素サイクル異常症の有病率の増加は、世界の市場の成長を促進する可能性が高いです。米国疾病予防管理センター（CDC）が発表した報告によると、尿素サイクル異常症の予測発生率は出生8500人に1人です。多くの症例が未診断のままであり、障害を持つ新生児は完全な診断がつかないまま死亡するため、正確な数は不明です。乳幼児突然死症候群（SIDS）の症例の最大20％は、尿素サイクル異常症のような先天性代謝異常の未診断に起因すると考えられており、尿素サイクル異常症治療市場を刺激すると予想されています。

患者における取り組みと意識の高まり

過去数年にわたり、各国の政府や民間団体は、市場の成長を後押しするためにいくつかの措置を講じてきました。研究開発への多額の投資、認知度向上プログラムの増加、広範な研究活動や臨床試験、規制機関による承認の容易さなどの調査イニシアチブの高まりが、市場を支える要因となっています。例えば、2017年にミード・ジョンソン・ニュートリション・カンパニー（MJN）はレキット・ベンキーザー・グループplc（RB）との合併を宣言しました。RBの一部門となったミード・ジョンソンは、尿素サイクル異常症の食事管理に使用されるEnfaとNutramigenをRBのコンシューマーヘルス・ポートフォリオに組み込み、世界的に認知されたブランドを獲得し、世界の地位を強化しました。同様に、2017年にHorizon Pharma plcは、尿素サイクル異常症に苦しむ個人のためのイニシアチブであるUCD in Commonを立ち上げ、UCD患者、その家族、医療専門家に教育的、支援的、双方向的なリソースを提供しています。

市場プレイヤー

Bausch Health Companies Inc.、Recordati Rare Diseases、Eurocept Pharmaceuticals Holding（Lucane Pharma SA）、Acer Therapeutics、Ultragenyx Pharmaceutical、Aeglea BioTherapeutics、Arcturus Therapeutics, Inc.、Orpharma Pty Ltd.、Selecta Biosciences, Inc.、Abbott Laboratories, Inc.などが、この市場で事業を展開する大手企業です。

利用可能なカスタマイズ

TechSciリサーチは、所定の市場データを用いて、企業の特定のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 世界の尿素サイクル異常症治療薬市場に与えるCOVID-19の影響

第4章 顧客の声

第5章 エグゼクティブサマリー

第6章 尿素サイクル異常症治療の世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 酵素欠損タイプ別（カルバミルリン酸合成酵素（CPS1）、N-アセチルグルタミン酸合成酵素（NAGS）、オルニチントランスカルバミラーゼ（OTC欠損）、アルギニノコハク酸合成酵素（AS）、アルギニノコハク酸リアーゼ（ALまたはASAリアーゼ）、アルギナーゼ（AG））
    • 治療タイプ別（アミノ酸製剤、フェニル酪酸塩、安息香酸ナトリウム、その他）
    • 投与経路別（経口剤／静脈注射剤）
    • 流通チャネル別（病院、小売薬局、オンライン薬局）
    • 企業別（2021年）
    • 地域別
  • 市場マップ

第7章 北米の尿素サイクル異常症治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 酵素欠損タイプ別
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 北米国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 欧州の尿素サイクル異常症治療市場展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 酵素欠損タイプ別
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋地域の尿素サイクル異常症治療市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 酵素欠損タイプ別
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米の尿素サイクル異常症治療市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 酵素欠損タイプ別
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの尿素サイクル異常症治療市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 酵素欠損タイプ別
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

第14章 競合情勢

  • Bausch Health Companies Inc.
  • Recordati Rare Diseases
  • Eurocept Pharmaceuticals Holding（Lucane Pharma SA）
  • Acer Therapeutics
  • Ultragenyx Pharmaceutical
  • Aeglea BioTherapeutics
  • Arcturus Therapeutics, Inc.
  • Orpharma Pty Ltd.
  • Selecta Biosciences, Inc
  • Abbott Laboratories, Inc.

第15章 戦略的提言

目次
Product Code: 12980

The global urea cycle disorders treatment market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the increasing prevalence of urea cycle disorder, and extensive research and development are driving the growth of the market globally. Urea cycle disorders (UCDs) are a group of genetic defects that constitute the urea cycle in the periportal liver cells. The other factors supporting the market's growth are rising investments in research and development activities by the government, increasing initiatives by key players, rising awareness among the masses, the presence of better healthcare services, and a growing number of innovative diagnostic approaches.

Rising Prevalence of urea cycle disorders among the Population

The growing prevalence of urea cycle disorders is likely to propel the growth of the market globally. According to reports published by the Centers for Disease Control and Prevention (CDC), the projected occurrence of urea cycle disorders is 1 in 8500 births. Owing to the many cases which remain undiagnosed and the newborns with the disorders die without a complete diagnosis; the exact numbers remain unknown. It is assumed that up to 20% of Sudden Infant Death Syndrome (SIDS) cases may be ascribed to an undiagnosed inborn error of metabolism, such as a urea cycle disorder which is anticipated to impel the urea cycle disorders treatment market.

Increasing Initiatives and Awareness Among Patients

Over the past few years, governments of different nations and private organizations have been taking several steps to bolster the growth of the market. Rising initiatives such as heavy investments in research and development, increase in awareness programs, extensive research activities and clinical trials, and ease in approvals by the regulatory bodies are the supporting factors for the market. For instance, in 2017, Mead Johnson Nutrition Company (MJN) declared its merger with Reckitt Benckiser Group plc (RB). Mead Johnson, now a division of RB, included its globally recognized brands, incorporating Enfa and Nutramigen, which are used in the dietary management of urea cycle disorder, to RB's consumer health portfolio, thus bolstering its position globally. Similarly, in 2017, Horizon Pharma plc launched UCD in Common, an initiative for individuals suffering from urea cycle disorder, to offer educational, supportive, and interactive resources to the patients residing with UCD, their families, and healthcare specialists.

Market Segmentation

The global urea cycle disorders treatment market is segmented into enzyme deficiency type, treatment type, route of administration, distribution channel, and company. Based on enzyme deficiency type, the market is divided into carbamyl phosphate synthetase (CPS1), N-acetyl glutamate synthetase (NAGS), ornithine transcarbamylase (OTC deficiency), argininosuccinic acid synthetase (AS), argininosuccinate lyase (AL or ASA lyase), and arginase (AG). Based on treatment type, the market is divided into amino acid formulas, phenylbutyrate, sodium benzoate, and others. Based on the route of administration, the market is divided into oral and intravenous. Based on distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of cases of urea cycle diseases in the country.

Market Players

Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global urea cycle disorders treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type:

  • Carbamyl Phosphate Synthetase (CPS1)
  • N-Acetylglutamate Synthetase (NAGS)
  • Ornithine Transcarbamylase (OTC Deficiency)
  • Argininosuccinic Acid Synthetase (AS)
  • Argininosuccinate Lyase (AL or ASA Lyase)
  • Arginase (AG)

Urea Cycle Disorders Treatment Market, By Treatment Type:

  • Amino Acid Formulas
  • Phenylbutyrate
  • Sodium Benzoate
  • Others

Urea Cycle Disorders Treatment Market, By Route of Administration:

  • Oral
  • Intravenous

Urea Cycle Disorders Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Urea Cycle Disorders Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Urea Cycle Disorders Treatment Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Urea Cycle Disorders Treatment Market

4. Voice of Customer

5. Executive Summary

6. Global Urea Cycle Disorders Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG))
    • 6.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others)
    • 6.2.3. By Route of Administration (Oral v/s Intravenous)
    • 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region
  • 6.3. Market Map

7. North America Urea Cycle Disorders Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Enzyme Deficiency Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Urea Cycle Disorders Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Enzyme Deficiency Type
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Mexico Urea Cycle Disorders Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Enzyme Deficiency Type
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Canada Urea Cycle Disorders Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Enzyme Deficiency Type
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel

8. Europe Urea Cycle Disorders Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Enzyme Deficiency Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Urea Cycle Disorders Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Enzyme Deficiency Type
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. Germany Urea Cycle Disorders Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Enzyme Deficiency Type
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Enzyme Deficiency Type
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Italy Urea Cycle Disorders Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Enzyme Deficiency Type
        • 8.3.4.2.2. By Treatment Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Spain Urea Cycle Disorders Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Enzyme Deficiency Type
        • 8.3.5.2.2. By Treatment Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Asia-Pacific Urea Cycle Disorders Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Enzyme Deficiency Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Urea Cycle Disorders Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Enzyme Deficiency Type
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. India Urea Cycle Disorders Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Enzyme Deficiency Type
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Japan Urea Cycle Disorders Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Enzyme Deficiency Type
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel
    • 9.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Enzyme Deficiency Type
        • 9.3.4.2.2. By Treatment Type
        • 9.3.4.2.3. By Route of Administration
        • 9.3.4.2.4. By Distribution Channel
    • 9.3.5. Australia Urea Cycle Disorders Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Enzyme Deficiency Type
        • 9.3.5.2.2. By Treatment Type
        • 9.3.5.2.3. By Route of Administration
        • 9.3.5.2.4. By Distribution Channel

10. South America Urea Cycle Disorders Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Enzyme Deficiency Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Enzyme Deficiency Type
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Argentina Urea Cycle Disorders Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Enzyme Deficiency Type
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Colombia Urea Cycle Disorders Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Enzyme Deficiency Type
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Middle East and Africa Urea Cycle Disorders Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Enzyme Deficiency Type
    • 11.2.2. By Treatment Type
    • 11.2.3. By Route of Administration
    • 11.2.4. By Distribution Channel
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Urea Cycle Disorders Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Enzyme Deficiency Type
        • 11.3.1.2.2. By Treatment Type
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By Distribution Channel
    • 11.3.2. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Enzyme Deficiency Type
        • 11.3.2.2.2. By Treatment Type
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By Distribution Channel
    • 11.3.3. UAE Urea Cycle Disorders Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Enzyme Deficiency Type
        • 11.3.3.2.2. By Treatment Type
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Bausch Health Companies Inc.
  • 14.2. Recordati Rare Diseases
  • 14.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
  • 14.4. Acer Therapeutics
  • 14.5. Ultragenyx Pharmaceutical
  • 14.6. Aeglea BioTherapeutics
  • 14.7. Arcturus Therapeutics, Inc.
  • 14.8. Orpharma Pty Ltd.
  • 14.9. Selecta Biosciences, Inc
  • 14.10. Abbott Laboratories, Inc.

15. Strategic Recommendations